TxCell receives EU Orphan Drug Designation for Col-Treg in the treatment of non-infectious uveitis

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory...